Key facts
| Price (PPV) | 11,326 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | ofatumumab |
| Class | ANTINEOPLASIQUES ET IMMUNOMODULATEURS |
| Manufacturer | NOVARTIS PHARMA MAROC |
| Presentation | Boite unitaire |
| Hospital price | 11,112 MAD |
| Data collected on | 9/8/2026 |
Indications
Bonspri est indiqué pour le traitement des patients adultes atteints de formes récurrentes de sclérose en plaques (SEP) afin de retarder la progression de l'incapacité physique et réduire la fréquence des rechutes
Find an open pharmacy
On-call pharmacies near you
About Bonspri 20 mg
Bonspri 20 mg belongs to the antineoplasiques et immunomodulateurs therapeutic class. In Morocco, this drug is marketed by NOVARTIS PHARMA MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Bonspri 20 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Bonspri 20 mg
Answers to common questions from Moroccan patients about this drug.